Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.54 |
| ▸ | STAT3 | P40763 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 7/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6449064 | 0.84 | NPC1 (0.66) | SMN1; SMN2NPC1STAT3RAB9AGAA | |
| SCHEMBL6452299 | 0.84 | L3MBTL1 (0.51) | SMN1; SMN2NPC1RAB9AGAAMEN1 | |
| SCHEMBL6448795 | 0.82 | KAT6A (0.54) | SMN1; SMN2NPC1RAB9AGAALMNA | |
| SCHEMBL6448406 | 0.82 | TLR7 (0.56) | SMN1; SMN2NPC1RAB9AGAAMEN1 | |
| SCHEMBL6470094 | 0.81 | LMNA (0.53) | SMN1; SMN2NPC1STAT3RAB9AGAA | |
| SCHEMBL15988864 | 0.81 | NFE2L2 (0.54) | SMN1; SMN2NPC1NFE2L2RAB9AGAA | |
| SCHEMBL6451241 | 0.79 | TMPRSS4 (0.51) | SMN1; SMN2NPC1NFE2L2RAB9AGAA | |
| SCHEMBL15988758 | 0.76 | CTNNB1 (0.60) | NFE2L2RAB9AMAPTMAOB | |
| SCHEMBL6448607 | 0.75 | RAB9A (0.63) | SMN1; SMN2NPC1STAT3RAB9AGAA | |
| SCHEMBL2346222 | 0.74 | L3MBTL1 (0.55) | NFE2L2GAAALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | SMN1; SMN2 4633/4885NPC1 59/4885NFE2L2 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.